title: [Renal insufficiency and breast cancer].
abstract: The Renal Insufficiency and Anticancer Medications (IRMA) study is a French national, observational study, which demonstrated the high prevalence of abnormal renal function in a population of 4,684 solid tumour patients, treated in 15 cancer centers. Among them, 7.2% had a SCR level ≥ 110 mmol/L. In the 1,898 patients with breast cancer, only 31 patients (1.63%) had a SCR level ≥ 110 mmol/L. Nevertheless, respectively 51.8 and 50.8% had a creatinine clearance estimated with the Cockcroft-Gault and aMDRD formulae, below 90 mL/min. Even if the most used medications (anthracyclins, taxanes, trastuzumab, hormone therapies) are not nephrotoxic, these results are important because bevacizumab modifies the need for renal management. In case of renal insufficiency, some other treatments such biphosphonates IV, capecitabin and platin salts need drug dosage adjustment or interruption.
authors: Institut Curie, département oncologie médicale, Paris, France. philippe.beuzeboc@curie.net
authors: Philippe
authors: P
authors: Beuzeboc
authors: Christophe
authors: C
authors: Le Tourneau
authors: Joseph
authors: J
authors: Gligorov
authors: Nicolas
authors: N
authors: Janus
authors: Jean-Philippe
authors: JP
authors: Spano
authors: Isabelle
authors: I
authors: Ray-Coquard
authors: Gilbert
authors: G
authors: Deray
authors: Vincent
authors: V
authors: Launay-Vacher
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D003404:Creatinine / Q000378:metabolism; D003681:Dehydration / Q000150:complications; D004164:Diphosphonates / Q000009:adverse effects; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D007668:Kidney / Q000187:drug effects*; D008875:Middle Aged; D051437:Renal Insufficiency / Q000150:complications* / Q000378:metabolism; D055815:Young Adult; D000077211:Zoledronic Acid
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D000068258:Bevacizumab; D000077211:Zoledronic Acid; D003404:Creatinine